Journal of Diabetes最新文献

{"title":"Assessing and predicting type 2 diabetes risk with triglyceride glucose-body mass index in the Chinese nondiabetic population—Data from long-term follow-up of Da Qing IGT and Diabetes Study","authors":"Haixu Wang,&nbsp;Siyao He,&nbsp;Jinping Wang,&nbsp;Xin Qian,&nbsp;Bo Zhang,&nbsp;Zhiwei Yang,&nbsp;Bo Chen,&nbsp;Guangwei Li,&nbsp;Qiuhong Gong,&nbsp;for the Da Qing Diabetes Prevention Outcome Study Group","doi":"10.1111/1753-0407.70001","DOIUrl":"10.1111/1753-0407.70001","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We intended to characterize the superiority of triglyceride glucose-body mass index (TyG-BMI) in predicting type 2 diabetes mellitus (T2DM) compared with triglyceride glucose (TyG) and homeostatic model assessment for insulin resistance (HOMA-IR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 699 nondiabetic participants in the Da Qing IGT and Diabetes Study were involved in the present analysis and classified according to the median of baseline TyG-BMI, namely the G1 (low TyG-BMI) and G2 (high TyG-BMI) groups. Information on developing diabetes was assessed from 1986 to 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the 34-year follow-up, after adjustment for confounders, the G2 group had a higher risk of developing type 2 diabetes than the G1 group (hazard ratio [HR]: 1.92, 95% confidence interval [CI]: 1.51–2.45, <i>p</i> &lt; 0.0001). Restricted cubic spline analyses showed that increased TyG-BMI was linearly related to higher risks of type 2 diabetes (<i>p</i> for non-linearity&gt;0.05). Time-dependent receiver operator characteristics curves suggested that TyG-BMI exhibited higher predictive ability than TyG (6-year: area under the curve [AUC]_TyG-BMI vs. AUC_TyG, 0.78 vs. 0.70, <i>p</i> = 0.03; 34-year: AUC_TyG-BMI vs. AUC_TyG, 0.79 vs. 0.73, <i>p</i> = 0.04) and HOMA-IR (6-year: AUC_TyG-BMI vs. AUC_HOMA-IR, 0.78 vs. 0.70, <i>p</i> = 0.07; 34-year: AUC_TyG-BMI vs. AUC_HOMA-IR, 0.79 vs. 0.71, <i>p</i> = 0.04) in both short and long terms, and the thresholds of TyG-BMI to predict type 2 diabetes were relatively stable (195.24–208.41) over the 34-year follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this post hoc study, higher TyG-BMI was associated with an increased risk of type 2 diabetes and demonstrated better predictability than TyG and HOMA-IR, favoring the application of TyG-BMI as a potential tool for evaluating the risk of type 2 diabetes in clinical practice.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 10","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide-1 receptor agonists and kidney outcomes","authors":"Richard J. MacIsaac,&nbsp;Philippa Trevella,&nbsp;Elif I. Ekinci","doi":"10.1111/1753-0407.13609","DOIUrl":"10.1111/1753-0407.13609","url":null,"abstract":"<p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney-protective effect of the GLP-1RA class of medications has been derived from kidney-related outcomes reported from cardiovascular outcome trials (CVOTs). GLP-1RAs have been shown to reduce albuminuria, mitigate cardiovascular risk, and possibly attenuate estimated glomerular filtration rate (eGFR) decline. The kidney-protective effects of GLP-1RAs are thought to be attributed to their anti-inflammatory, antioxidant, and vasodilatory properties. Despite these promising findings, the use of GLP-RAs has yet to be definitively shown to slow progression to chronic kidney failure in people with T2DM. The Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW trial) is the first major trial assessing the potential of a GLP-1RA to slow progression of kidney disease in people with established CKD to clinically important kidney end points. On March 5, 2024, the top line result from FLOW was announced with semaglutide 1.0 mg being reported to reduce the primary end point of the trial by a significant 24% compared with placebo. Here, we summarize the kidney outcomes reported from CVOTs for the GLP-1RA class of medication and briefly describe kidney outcomes from other major GLP-1RAs trials. We also discuss a potential role of the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, as a kidney-protective agent.</p><p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 10","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is in a name and other peeves","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.70017","DOIUrl":"https://doi.org/10.1111/1753-0407.70017","url":null,"abstract":"&lt;p&gt;“What's in a name? That which we call a rose, by any other word would smell as sweet.”&lt;/p&gt;&lt;p&gt;William Shakespeare, Romeo and Juliet (Act 2, Scene 2)&lt;/p&gt;&lt;p&gt;A number of submissions to the Journal of Diabetes appear to share similar flaws, and it might be of interest to potential authors to understand some of the characteristics which lead the Editors to look unfavorably on such.&lt;/p&gt;&lt;p&gt;We have lately noticed quite a few submissions pertaining to associations of “remnant cholesterol” (RC) with various diabetes-related conditions and complications. A PubMed literature search suggests that this is not only true for our Journal, but also has led to many recent publications (Figure 1). Does this reflect some new knowledge of the nature of atherogenic lipoproteins?&lt;/p&gt;&lt;p&gt;Such manuscripts calculate RC as (total cholesterol [TC]—high-density lipoprotein cholesterol [HDL-C]—low-density lipoprotein cholesterol [LDL-C]). However, most of these use the Friedewald equation for LDL calculation, as LDL-C = (TC) − (HDL-C) − (triglyceride[TG]/5).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Hence, for most such studies, RC algebraically is simply TG/5. Direct LDL measurements can be employed to more accurately estimate RC, but, if applied to persons not having marked hypertriglyceridemia (&gt;400 mg/dL), RC remains strongly related to TG.&lt;/p&gt;&lt;p&gt;Recall that TG levels below 400 mg/dL are associated with insulin resistance.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Recognizing this, the myriad recent publications showing that RC correlates with CVD (cardiovascular disease),&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; cognitive impairment,&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; visceral adipose tissue,&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; chronic kidney disease,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; “metabolically unhealthy obesity”,&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; metabolic dysfunction-associated steatotic liver disease,&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; and so on appear likely to be a restatement of previously recognized associations.&lt;/p&gt;&lt;p&gt;Another “peeve” is the receipt of a manuscript studying an index based on the sum or ratio of several factors associated with a diabetes-related endpoint. For example, insulin resistance is associated both with low HDL-C and with elevations in alanine aminotransferase (ALT). If one calculates the ALT/HDL-C ratio, then mathematically one would expect an association with insulin resistance, which might have a numerically greater correlation than with either parameter individually.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; However, unless the proposed new ratio allows a conceptual advance to be made, we would tend to think that little novel understanding would ensue.&lt;/p&gt;&lt;p&gt;Other studies have used, as a measure of insulin resistance in type 1 diabetes, the estimated glucose disposal rate, calculated as (estimated glucose disposal rate) eGDR = 24.31 − (12.22 × (waist-hip ratio) WHR) − (3.29 × [history (high blood pressure) HBP]) − (0.57 × HbA1c). It is certainly logical that such clinical factors would correlate with the glucose disposal rate, and an insulin c","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous glucose monitor metrics and hemoglobin A1c correlation in youth with diabetes: A retrospective analysis of real-world correlations","authors":"Jessica A. Schmitt,&nbsp;Meryl C. Nath,&nbsp;Joshua Richman,&nbsp;Joycelyn Atchison","doi":"10.1111/1753-0407.13602","DOIUrl":"https://doi.org/10.1111/1753-0407.13602","url":null,"abstract":"&lt;p&gt;Although factors other than glucose affect glycosylated hemoglobin A1c (HbA1c),&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt; HbA1c is used to monitor glycemia.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Studies have shown racial differences&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; and variations&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; in continuous glucose monitor (CGM)-measured mean glucose and laboratory HbA1c values. CGM use in youth has increased&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;; however, optimal utilization of CGM metrics as a proxy for HbA1c, particularly in specific populations, remains uncertain.&lt;/p&gt;&lt;p&gt;We aimed to evaluate the correlation of CGM metrics to HbA1c in youth with type 1 diabetes, identify the strongest correlation, and determine if patient characteristics significantly mitigate correlations. We reviewed data from non-Hispanic White (NHW) and non-Hispanic Black (NHB) youth with type 1 diabetes at Children's of Alabama from July 2019 to January 2022. Data included HbA1c, demographics, duration of diabetes, type of insulin administration, and CGM data from 14 and 90 days before HbA1c measurement. As the goal was to assess the correlation of CGM metrics and HbA1c in real-world use, there was no requirement for days or percentage of days for CGM use for data inclusion.&lt;/p&gt;&lt;p&gt;Demographics and metrics were inspected by summary statistics and compared between groups using distribution-appropriate bivariate tests. We examined smoothed scatterplots between each metric and HbA1c stratified by subject characteristics. After plots suggested no important nonlinear trends or interactions, we identified which metrics were most strongly related to HbA1c using linear regression and repeated this for subcohorts stratified by patient characteristics including: HbA1c cohorts (adequate, moderate, and poor glycemic management as defined by HbA1c: &lt;7.5% [58 mmol/mol], 7.5%–9.5% [58–80 mmol/mol], and &gt;9.5% [80 mmol/mol]), race, sex, age, and duration of diabetes. Finally, for high-ranking measures, we fit regression models adjusted for CGM metric along with patient characteristics to check whether the model coefficient of the metric changed appreciably.&lt;/p&gt;&lt;p&gt;In total, 205 youth were included. Forty-four (21.5%) were NHB, in line with the demographics of this clinic.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; A minority (&lt;i&gt;n&lt;/i&gt; = 45, 22.0%), were publicly insured. Median age was 16.5 years (interquartile range [IQR]: 14.0–18.1) with a duration of diabetes of 5.7 years (IQR: 2.8–10.2). Ninety-eight (47.8%) were female, and approximately half (&lt;i&gt;n&lt;/i&gt; = 94, 49.7%) used an insulin pump. Eighty-three (40.5%) were in the lowest HbA1c cohort, 42 (20.5%) were in the mid-HbA1c cohort, and 80 (39.0%) were in the highest HbA1c cohort.&lt;/p&gt;&lt;p&gt;Except for coefficient of variation, all CGM metrics were strongly associated with HbA1c with 90-day mean glucose being the most strongly correlated (&lt;i&gt;r&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.79, &lt;i&gt;p&lt;/i&gt; &lt; 0.01), followed by 90-day glucose management index (&lt;i&gt;r&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.77, &lt;i&gt;p&lt;/i&gt; &lt; 0.01) (see Table","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13602","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose–response meta-analysis based on animal models","authors":"Xiaojing Liu,&nbsp;Xia Gu,&nbsp;Jiao Zhang,&nbsp;Xiangmeng Li,&nbsp;Xiansen Wei,&nbsp;Shimin Jiang,&nbsp;Wenge Li","doi":"10.1111/1753-0407.13608","DOIUrl":"https://doi.org/10.1111/1753-0407.13608","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Accumulating experimental evidence has shown that resveratrol supplementation is effective for treating diabetic nephropathy (DN) in animal models. In this systematic review and meta-analysis, we assessed the effects and multiple mechanisms of resveratrol in animal models of DN.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Before September 2023, preclinical literature was systematically searched and screened across PubMed, Web of Science, EMBASE, and the Cochrane Library. Forty-two studies were included, and the risk of bias tool from SYRCLE was used to assess the methodological quality. Pooled overall effect sizes of the results were generated by STATA 16.0.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The overall results provide preliminary evidence that the consumption of resveratrol can significantly reduce the mesangial index, glomerular basement membrane thickness, glomerular hypertrophy, serum creatinine, blood urea nitrogen, 24-h urinary protein, blood glucose, kidney index, total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels. In contrast, the levels of albumin and high-density lipoprotein cholesterol are significantly increased. However, resveratrol did not significantly reduce creatinine clearance or glycated hemoglobin levels. Dose–response analysis revealed that resveratrol was most effective at improving kidney function and reducing DN when administered at lower doses of ≤15 mg/kg/day or higher doses of 100–200 mg/kg/day, with significant improvements in biochemical kidney injury markers and a better effect on dysglycemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The benefits of resveratrol in DN are likely due to its anti-inflammatory, antioxidant, metabolic regulatory, and autophagy-promoting effects. To confirm these findings for clinical use, further large-scale, long-term, high-quality preclinical trials are warranted to accurately assess the anti-DN effects and safety of resveratrol.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13608","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel nonsense mutation c.747C>G in the NEUROD1 gene detected within a Chinese family affected by maturity-onset diabetes of the young type 6","authors":"Yuwen Li,&nbsp;Qian Wen,&nbsp;Huige Shao,&nbsp;Meng Hao,&nbsp;Yihu Sun,&nbsp;Ting Liu","doi":"10.1111/1753-0407.13607","DOIUrl":"https://doi.org/10.1111/1753-0407.13607","url":null,"abstract":"<p><b>Highlights</b></p><p>\u0000 </p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13607","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycated albumin levels are associated with adverse stroke outcomes in patients with acute ischemic stroke in China","authors":"Jiawen Mao,&nbsp;Meng Wang,&nbsp;Chunjuan Wang,&nbsp;Hongqiu Gu,&nbsp;Xia Meng,&nbsp;Yong Jiang,&nbsp;Xin Yang,&nbsp;Jing Zhang,&nbsp;Yunyun Xiong,&nbsp;Xingquan Zhao,&nbsp;Liping Liu,&nbsp;Yilong Wang,&nbsp;Yongjun Wang,&nbsp;Zixiao Li,&nbsp;Bihong Zhu","doi":"10.1111/1753-0407.13600","DOIUrl":"https://doi.org/10.1111/1753-0407.13600","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Glycated albumin (GA) is a biomarker monitoring glycemia 2–4 weeks before stroke onset. This study was designed to explore the association between GA levels with poststroke outcomes in patients with acute ischemic stroke or transient ischemic attack (TIA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Participants with ischemic stroke or TIA who had a baseline GA measurement were included in the Third China National Stroke Registry study. The effect of GA on stroke recurrence, poor functional outcomes, and combined vascular events was examined during the 1-year follow-up period. Multivariate Cox and logistic regression models were performed to evaluate the association. Discrimination tests were used to examine the incremental predictive value of GA when incorporating it into the conventional model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 3861 participants were enrolled. At the 3-month follow-up, the elevated GA level was associated with an increased risk of poor functional outcomes (adjusted odds ratio [OR], 1.45; 95% confidence interval [CI], 1.01–2.09). A similar increase was observed for stroke recurrence (adjusted hazard ratio [HR], 1.56; 95% CI, 1.09–2.24), poor functional outcomes (adjusted OR, 1.62; 95% CI, 1.07–2.45), and combined vascular events (adjusted HR, 1.55; 95% CI, 1.09–2.20) at the 1-year follow-up. In nondiabetic patients, the association between GA and poor functional outcomes was more pronounced (adjusted OR, 1.62; 95% CI, 1.05–2.50). Adding GA into the conventional model resulted in slight improvements in predicting poor functional outcomes (net reclassification improvement [NRI]: 12.30% at 1 year).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study demonstrated that elevated GA levels in serum were associated with stroke adverse outcomes, including stroke recurrence, poor functional outcomes, and combined vascular events, in patients with ischemic stroke or TIA.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13600","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fasting blood glucose level and risk of all-cause and cause-specific mortality in peritoneal dialysis patients","authors":"So Jin Lim,&nbsp;Ju Young Moon,&nbsp;Kyung Hwan Jeong,&nbsp;Gang Jee Ko,&nbsp;Yun Jin Choi,&nbsp;Hyeon Seok Hwang","doi":"10.1111/1753-0407.13601","DOIUrl":"https://doi.org/10.1111/1753-0407.13601","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Glycemic control is crucial in peritoneal dialysis (PD) patients with diabetes. Although fasting blood glucose (FBG) is the most commonly used index to measure blood glucose levels, there is currently no evidence supporting the association between FBG level and mortality risk in PD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 3548 diabetic PD patients between 2002 and 2018 were enrolled from the National Health Insurance Service database of Korea. We investigated the association between FBG levels and the risk of all-cause and cause-specific mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with FBG levels 80–99 mg/dL exhibited the highest survival rates, whereas those with FBG levels ≥180 mg/dL had the lowest survival rates. Compared with FBG levels 80–99 mg/dL, the adjusted hazard ratios and 95% confidence interval for all-cause mortality significantly increased as follows: 1.02 (0.87–1.21), 1.41 (1.17–1.70), 1.44 (1.18–2.75), and 2.05 (1.73–2.42) for patients with FBG 100–124 mg/dL, FBG 125–149 mg/dL, FBG 150–179 mg/dL, and FBG ≥180 mg/dL, respectively. The risk for all-cause mortality also showed an increasing pattern in patients with FBG levels &lt;80 mg/L. The risk of cardiovascular death significantly increased as FBG levels exceeded 125 mg/dL. However, the risk of infection-related and malignancy-related deaths did not show a significant increase with increasing FBG levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There was an increase in the risk of all-cause mortality as FBG levels exceeded 125 mg/dL in PD patients with diabetes, and the risk of cardiovascular death showed a strong correlation with FBG levels compared with other causes of death.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13601","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of patient-centered self-management intervention on glycemic control, self-efficacy, and self-care behaviors in South Asian adults with type 2 diabetes mellitus: A multicenter randomized controlled trial","authors":"Kainat Asmat,&nbsp;Erika Sivarajan Froelicher,&nbsp;Khairunnisa Aziz Dhamani,&nbsp;Raisa Gul,&nbsp;Nazeer Khan","doi":"10.1111/1753-0407.13611","DOIUrl":"https://doi.org/10.1111/1753-0407.13611","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to test the efficacy of patient-centered self-management intervention (PACE-SMI) to improve HbA1c, self-efficacy, and self-care behaviors in adults with type 2 diabetes mellitus (T2DM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this multicenter, parallel two-arm randomized controlled trial, 612 adults with T2DM and HbA1c ≥ 7% were enrolled and assigned to the control group (<i>n</i> = 310) and the intervention group (<i>n</i> = 302) using stratified permuted block randomization. The control group received usual care, whereas the intervention group received usual care plus nurse-led, theory-driven, culturally tailored PACE-SMI, comprising eight weekly sessions of individualized education, counseling, behavioral training, and home visit. Outcomes were assessed at baseline, postintervention, and 3 months follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data at 3 months were provided by 583 participants (control: <i>n</i> = 295, intervention: <i>n</i> = 288). Per-protocol analysis showed that the intervention group had a lower mean HbA1c (8.49% [standard deviation (SD), 1.58]) than the control group (8.74% [SD, 1.62]), with small yet statistically significant mean difference of 0.25% (95% confidence interval [CI], −0.01 to 0.51; Cohen's <i>d</i> = 0.16; <i>p</i> = 0.03). Self-efficacy and self-care behaviors significantly improved in the intervention group (116.89 [SD, 25.50] and 70.01 [SD, 17.97]) compared to the control group (75.43 [SD, 18.99] and 51.54 [SD, 12.04]), with mean differences of 41.48 (95% CI, 37.83–45.13; Cohen's <i>d</i> = 1.84; <i>p</i> &lt; 0.0001) and 18.56 (95% CI, 16.08–21.04; Cohen's <i>d</i> = 1.22; <i>p</i> &lt; 0.0001), respectively. Linear regression analysis indicated the effect of PACE-SMI on HbA1c was significantly mediated by improvements in self-efficacy and self-care behaviors (<i>R</i>² = 0.232, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PACE-SMI led to modest but significant improvement in HbA1c and substantial enhancements in self-efficacy and self-care behaviors in adults with T2DM.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13611","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type B insulin resistance syndrome induced by anti-PD-1 therapy","authors":"Xiaomin Shi,&nbsp;Mengyu He,&nbsp;Li Ni,&nbsp;Zhijuan Dai,&nbsp;Mengte Shi,&nbsp;Yingying Zhou,&nbsp;Huabing Zhang,&nbsp;Ming Li,&nbsp;Chaoming Wu","doi":"10.1111/1753-0407.13603","DOIUrl":"https://doi.org/10.1111/1753-0407.13603","url":null,"abstract":"&lt;p&gt;A 59-year-old man was diagnosed with Hodgkin lymphoma in May 2020 and began treatment with sintilimab in August 2020. The patient had a normal blood glucose test before receiving treatment with sintilimab, with no family history of diabetes. In September 2020, the patient developed diabetic ketoacidosis after receiving three cycles of sintilimab. Glycated hemoglobin A1c (HbA1c) was 7.0%, and C-peptide level was undetectable. Diabetes-related antibodies, including glutamic acid decarboxylase antibody, insulinoma-associated protein 2 antibodies, and insulin autoantibodies, were all negative. Based on these findings, he was diagnosed with fulminant type 1 diabetes caused by anti-programmed cell death-1 (anti-PD-1) therapy. Additionally, he was also diagnosed with destructive thyroiditis caused by anti-PD-1 therapy at the same time. After discharge, he received insulin therapy, and his glucose level fluctuated between 4 and 20 mmol/L. The treatment regimen for Hodgkin's lymphoma was modified, and sintilimab treatment was stopped. Two months later, the Hodgkin's lymphoma was resolved.&lt;/p&gt;&lt;p&gt;In November 2021, the patient was admitted to the endocrinology department due to significant weight loss. In the 3 months leading up to his admission, he had lost about 15 kg in weight, with a poor glucose control (often &gt;33.3 mmol/L). He did not report any symptoms of nausea or vomiting. On physical examination, he weighed 47 kg and had a body mass index (BMI) of 16.65 kg/m&lt;sup&gt;2&lt;/sup&gt;. On admission, his plasma glucose level was 29.9 mmol/L, and β-hydroxybutyric level was 0.3 mmol/L. Of note, his serum C-peptide was &lt;0.05 ng/mL, while his serum insulin level was &gt;300 mU/L, and his HbA1c level was 10.2%. He was commenced on intravenous regular insulin therapy, and the insulin dose was gradually increased. However, despite continuous intravenous infusion of up to 3200 U of regular insulin daily, his blood glucose was still above 15 mmol/L. Other examinations showed that serum triglyceride was 0.89 mmol/L, adiponectin was 25.15 μg/mL, and insulin-like growth factor-1 was &lt;25 ng/mL. Diabetes-related antibodies were all negative as before.&lt;/p&gt;&lt;p&gt;We measured his serum insulin receptor antibody by using enzyme linked immunosorbent assay, which was developed in Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital. This patient had a positive result on the insulin receptor antibody test. He was therefore diagnosed with type B insulin resistance syndrome (TBIRS). During this admission, he was also diagnosed with Sjogren's syndrome and hemolytic anemia. We commenced him on an immunosuppressive regimen, combining iv rituximab (0.5 g), cyclophosphamide (0.4 g), and glucocorticoids. Glucocorticoids were administered as methylprednisolone 500 mg intravenously for 3 days, followed by a maintenance dose of 50 mg po daily, with a prolonged taper. Hydroxychloroquine was administered in a dose of 0.2 mg po daily continuo","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13603","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}